{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:43:32Z","timestamp":1792604612624,"version":"4.5.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>People with sickle cell disease (SCD) are living longer, but their lives are impacted even more by the unpredictable intermittent or constant pain that is often poorly managed over a lifetime. To address this problem, an interdisciplinary team approach is needed that brings the medical professionals together for optimal compassionate care that is coordinated from the beginning of life and throughout the patient\u2019s lifespan.The hematologist, whenever possible, should take the lead. Effective models that have been developed to address SCD pain, such as the Day Hospital, The Recidivism Project and various Home Care models, need to be integrated into an overarching plan on a continuum with an underpinning philosophy that will sustain such a program. While the focus of palliative care has been end of life, its philosophies fit the chronic disease model and support an integrated team approach to the SCD pain management dilemma. The patient-focused and family-oriented interventions can be modeled to fit \u201cany place, any time,\u201d outpatient, inpatient or the home, with homecare and other support systems. Such are the needs in SCD: appropriate, timely and compassionate care to prevent or relieve suffering and to preserve dignity, meaning, value and quality of life with improvement that is translational from birth until the end of life.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.466","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T10:12:58Z","timestamp":1228990378000},"page":"466-474","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Pain Management in Sickle Cell Disease: Palliative Care Begins at Birth?"],"prefix":"10.1182","volume":"2008","author":[{"given":"Lennette","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111708460197000_R1","doi-asserted-by":"crossref","unstructured":"Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg. 2007;13:534\u2013542.","DOI":"10.1213\/01.ane.0000268145.52345.55"},{"key":"2019111708460197000_R2","unstructured":"Benjamin LJ. The nature and management of acute painful episode in sickle cell disease. In: Forget BG, Higgs D, Nagel RL, Steinberg MH, eds. Disorders of Hemoglobin. Cambridge, UK: Cambridge University Press; 2001:671\u2013710."},{"key":"2019111708460197000_R3","doi-asserted-by":"crossref","unstructured":"Bonds DR. Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype. Blood Rev. 2005;19:99\u2013110.","DOI":"10.1016\/j.blre.2004.04.002"},{"key":"2019111708460197000_R4","doi-asserted-by":"crossref","unstructured":"Bradshaw DH, Nakamura Y, Chapman CR. National Institutes of Health grant awards for pain, nausea, and dyspnea research: an assessment of funding patterns. J Pain. 2005;6:277\u2013293.","DOI":"10.1016\/j.jpain.2005.01.362"},{"key":"2019111708460197000_R5","unstructured":"Benjamin LJ, Dampier CD, Jacox AK, et al. Guideline for the Management of Acute and chronic Pain in Sickle-Cell Disease. APS Clinical Practice Guidelines Series No 1. Glenview, IL; 1999."},{"key":"2019111708460197000_R6","doi-asserted-by":"crossref","unstructured":"Dunlop RJ, Bennett KCLB. Pain management for sickle cell disease [review]. Cochrane Database Syst Rev.2006 Apr 19;(2):CD003350.","DOI":"10.1002\/14651858.CD003350.pub2"},{"key":"2019111708460197000_R7","doi-asserted-by":"crossref","unstructured":"Ress DC, Lujohungbe AD, Parker NE, Stephens AD, Telfer P, Wright J. Guidelines for the management of acute painful crisis in sickle cell disease. Br J Haematol. 2003;120:744\u2013752.","DOI":"10.1046\/j.1365-2141.2003.04193.x"},{"key":"2019111708460197000_R8","doi-asserted-by":"crossref","unstructured":"Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129\u2013151.","DOI":"10.1080\/mic.11.2.129.151"},{"key":"2019111708460197000_R9","doi-asserted-by":"crossref","unstructured":"Alexander N, Higgs D, Dover G, Sergeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol. 2004;126: 606\u2013611.","DOI":"10.1111\/j.1365-2141.2004.05025.x"},{"key":"2019111708460197000_R10","doi-asserted-by":"crossref","unstructured":"Stuart MJ, Nagel RL. Sickle cell disease. Lancet. 2004;364:1343\u20131360.","DOI":"10.1016\/S0140-6736(04)17192-4"},{"key":"2019111708460197000_R11","unstructured":"Ballas SK. Sickle Cell Pain. Progress in Pain Research and Management. Vol 11. Seattle, WA: IASP Press; 1998."},{"key":"2019111708460197000_R12","unstructured":"The Management of Sickle Cell Disease. US Department of Health and Human Services, National Institute of Health, National Heart Lung and Blood Institute, Division of Blood Diseases and Resources. NIH Publication No. 02-2117, Fourth Edition. 2002."},{"key":"2019111708460197000_R13","unstructured":"Dampier C, Setty BNY, Eggleston B, Brodecki D, O\u2019Neal P, Stuart M. Vaso-occlusion in children with sickle cell disease: Clinical characteristics and biologic correlates. J Pediatr Hematol Oncol. 2004;29:785\u2013790."},{"key":"2019111708460197000_R14","doi-asserted-by":"crossref","unstructured":"Werner EM, Treadwell M, Hassell K, Keller S, Levine R. Sickle Cell Disease Health-Related Quality of Life Questionnaire Project [abstract]. Blood. 2006;108. Abstract #3339.","DOI":"10.1182\/blood.V108.11.3339.3339"},{"key":"2019111708460197000_R15","doi-asserted-by":"crossref","unstructured":"Benjamin LJ, Payne R. Pain in sickle cell disease. A multidimensional construct. In: Pace B, ed. Renaissance of Sickle Cell Disease Research in the Genome Era. London: Imperial College Press; 2007:99\u2013113.","DOI":"10.1142\/9781860947964_0007"},{"key":"2019111708460197000_R16","doi-asserted-by":"crossref","unstructured":"Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell patients-life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639\u20131644.","DOI":"10.1056\/NEJM199406093302303"},{"key":"2019111708460197000_R17","doi-asserted-by":"crossref","unstructured":"Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage. 2004;27:156\u2013169.","DOI":"10.1016\/j.jpainsymman.2003.12.001"},{"key":"2019111708460197000_R18","unstructured":"Pasero C, Paice JA, McCaffery M. Basic mechanics underlying the causes and effects of pain. In: McCaffery M, Pasero C, eds. Pain: Clinical Manual. St. Louis: Mosby, Inc; 1999:15\u201334."},{"key":"2019111708460197000_R19","doi-asserted-by":"crossref","unstructured":"Miller SC, Sleeper LA, Pegelow CH, et al. Predictions of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83\u201389.","DOI":"10.1056\/NEJM200001133420203"},{"key":"2019111708460197000_R20","doi-asserted-by":"crossref","unstructured":"McClain B, Kain ZN. Pediatric palliative care: a novel approach to children with sickle cell disease. Pediatrics. 2007;119:612\u2013614.","DOI":"10.1542\/peds.2006-3580"},{"key":"2019111708460197000_R21","unstructured":"Ely B, Tsao JCI. Pain in children\u2014early pain experiences can impact future health. The Pain Community News. 2008;8:5. www.painfoundation.org\/Publications\/PCN08winter.pdf."},{"key":"2019111708460197000_R22","doi-asserted-by":"crossref","unstructured":"Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle-cell disease: rates and risk factors. N Engl J Med. 1991;325:11\u201316.","DOI":"10.1056\/NEJM199107043250103"},{"key":"2019111708460197000_R23","doi-asserted-by":"crossref","unstructured":"Gil KM, Carson JW, Porter LS, et al. Daily stress and mood and their association with pain, healthcare use, and school activity in adolescents with sickle cell disease. J Ped Psych. 2003;28:363\u2013373.","DOI":"10.1093\/jpepsy\/jsg026"},{"key":"2019111708460197000_R24","doi-asserted-by":"crossref","unstructured":"Gil KM, Carson JW, Porter LS, et al. Daily mood and stress predict pain, health care use and work activity in African American adults with sickle cell disease. Health Psychol. 2004;23:267\u2013274.","DOI":"10.1037\/0278-6133.23.3.267"},{"key":"2019111708460197000_R25","doi-asserted-by":"crossref","unstructured":"Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17\u201325.","DOI":"10.1002\/ajh.20336"},{"key":"2019111708460197000_R26","doi-asserted-by":"crossref","unstructured":"Levenson JL, McClish DK, Dahman BA, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES Project. Psychosom Med. 2008;70:192\u2013196.","DOI":"10.1097\/PSY.0b013e31815ff5c5"},{"key":"2019111708460197000_R27","doi-asserted-by":"crossref","unstructured":"Rouse CM. Paradigms and politics: shaping health care access for sickle cell patients through the discursive regimes of biomedicine. Cult Med Psychiatry. 2004;28:369\u2013399.","DOI":"10.1023\/B:MEDI.0000046428.45980.eb"},{"key":"2019111708460197000_R28","doi-asserted-by":"crossref","unstructured":"Charache S, Terrin ML, Moore Rd, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317\u20131322.","DOI":"10.1056\/NEJM199505183322001"},{"key":"2019111708460197000_R29","doi-asserted-by":"crossref","unstructured":"Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148:939\u2013955.","DOI":"10.7326\/0003-4819-148-12-200806170-00221"},{"key":"2019111708460197000_R30","doi-asserted-by":"crossref","unstructured":"Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932\u2013938.","DOI":"10.7326\/0003-4819-148-12-200806170-00220"},{"key":"2019111708460197000_R31","doi-asserted-by":"crossref","unstructured":"Bonham VL. Race, ethnicity, and pain treatment: striving to understand the causes and solutions to the disparities in pain treatment. J Law Med Ethics. 2001;29:52\u201368.","DOI":"10.1111\/j.1748-720X.2001.tb00039.x"},{"key":"2019111708460197000_R32","doi-asserted-by":"crossref","unstructured":"Morrison RS, Wallenstein S, Natale D, Senzel RS, Huang LL. \u201cWe don\u2019t carry that\u201d \u2013 failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med. 2000;342:1023\u20131026.","DOI":"10.1056\/NEJM200004063421406"},{"key":"2019111708460197000_R33","doi-asserted-by":"crossref","unstructured":"Labbe E, Herbert D, Haynes J. Physician\u2019s attitude and practices in sickle cell disease pain management. J Pall Care. 2005;21:246\u2013251.","DOI":"10.1177\/082585970502100403"},{"key":"2019111708460197000_R34","doi-asserted-by":"crossref","unstructured":"Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol2005;79:17\u201325.","DOI":"10.1002\/ajh.20336"},{"key":"2019111708460197000_R35","doi-asserted-by":"crossref","unstructured":"Benjamin W, Swinson GI, Nagel R. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crisis. Blood. 2000;95:1130\u20131137.","DOI":"10.1182\/blood.V95.4.1130.003k03a_1130_1136"},{"key":"2019111708460197000_R36","doi-asserted-by":"crossref","unstructured":"Smith HS, Kirsh KL. Documentation and potential tools in long-term opioid therapy for pain. Med Clin N Am. 2007;91:213\u2013228.","DOI":"10.1016\/j.mcna.2006.10.005"},{"key":"2019111708460197000_R37","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9\u201319.","DOI":"10.1016\/j.pain.2004.09.012"},{"key":"2019111708460197000_R38","doi-asserted-by":"crossref","unstructured":"Ware M, Hambleton I, Ochaya I, Sergeant GR. Day care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol. 1999;104:93\u201396.","DOI":"10.1046\/j.1365-2141.1999.01160.x"},{"key":"2019111708460197000_R39","doi-asserted-by":"crossref","unstructured":"Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol. 2004;126:878\u2013880.","DOI":"10.1111\/j.1365-2141.2004.05123.x"},{"key":"2019111708460197000_R40","doi-asserted-by":"crossref","unstructured":"Schluger JH, Borg L, Ho A, Kreek MJ. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmocology. 2001;24:568\u2013575.","DOI":"10.1016\/S0893-133X(00)00222-0"},{"key":"2019111708460197000_R41","doi-asserted-by":"crossref","unstructured":"Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin N Am. 2007;91:199\u2013211.","DOI":"10.1016\/j.mcna.2006.10.003"},{"key":"2019111708460197000_R42","doi-asserted-by":"crossref","unstructured":"Lovick TA. Pro-nociceptive action of cholecystokinin in the periaqueductal grey: a role in neuropathic and anxiety-induced hyperalgesic states. Neurosci Biobehav Rev. 2008;32:852\u2013862.","DOI":"10.1016\/j.neubiorev.2008.01.003"},{"key":"2019111708460197000_R43","doi-asserted-by":"crossref","unstructured":"Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479\u2013496.","DOI":"10.1097\/AJP.0b013e31816b2f43"},{"key":"2019111708460197000_R44","doi-asserted-by":"crossref","unstructured":"Mercadante S, Ferraera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26:769\u2013775.","DOI":"10.1016\/S0885-3924(03)00258-6"},{"key":"2019111708460197000_R45","unstructured":"Bennett P, St Marie B. The Epidemiology of Pain. Core Curriculum for Pain Management Nursing. Philadelphia: W.B. Saunders Co; 2002:45\u201353."},{"key":"2019111708460197000_R46","doi-asserted-by":"crossref","unstructured":"McClish DK, Levenson JL, Penberthy LT, et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: the PiSCES Project. J Womens Health (Larchmt). 2006;15:146\u2013154.","DOI":"10.1089\/jwh.2006.15.146"},{"key":"2019111708460197000_R47","doi-asserted-by":"crossref","unstructured":"Smith W, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Int Med. 2008;148:95\u2013101.","DOI":"10.7326\/0003-4819-148-2-200801150-00004"},{"key":"2019111708460197000_R48","doi-asserted-by":"crossref","unstructured":"McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PISCES project. Health Qual Life Outcomes. 2005;3:50\u201357.","DOI":"10.1186\/1477-7525-3-50"},{"key":"2019111708460197000_R49","doi-asserted-by":"crossref","unstructured":"Dampier C, Ely B, Brodecki D, O\u2019Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 2002;23;461\u2013470.","DOI":"10.1054\/jpai.2002.128064"},{"key":"2019111708460197000_R50","unstructured":"Beyer JE, Simmons LE. Home treatment of pain for children and adolescents with sickle cell disease. Pain Mtg Nsg. 2004;5:126\u2013135."},{"key":"2019111708460197000_R51","doi-asserted-by":"crossref","unstructured":"Harrison OM, Edwards CL, Koenig HG, et al. Religiosity\/spirituality and pain in patients with sickle cell disease. J Nerv Mental Disease. 2005;193:250\u2013257.","DOI":"10.1097\/01.nmd.0000158375.73779.50"},{"key":"2019111708460197000_R52","doi-asserted-by":"crossref","unstructured":"Anghelescu DL, Oakes L, Hinds PS. Palliative care and pediatrics. Anesthesiology Clin N Am.2006;145\u2013161.","DOI":"10.1016\/j.atc.2005.11.001"},{"key":"2019111708460197000_R53","doi-asserted-by":"crossref","unstructured":"Pace B, ed. Renaissance of Sickle Cell Disease Research in the Genome Era. London: Imperial College Press; 2007.","DOI":"10.1142\/9781860947964"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/466\/786633\/466_474ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/466\/786633\/466_474ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:46:24Z","timestamp":1573980384000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/466\/95872\/Pain-Management-in-Sickle-Cell-Disease-Palliative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.466","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}